{'52WeekChange': -0.46396798,
 'SandP52WeekChange': 0.0644362,
 'address1': '75 Sidney Street',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 12.07,
 'askSize': 900,
 'averageDailyVolume10Day': 299787,
 'averageVolume': 323304,
 'averageVolume10days': 299787,
 'beta': 1.928282,
 'beta3Year': None,
 'bid': 12.05,
 'bidSize': 800,
 'bookValue': 2.157,
 'category': None,
 'circulatingSupply': None,
 'city': 'Cambridge',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 12.7,
 'dayLow': 12,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -5.262,
 'enterpriseToRevenue': 1.967,
 'enterpriseValue': 230610832,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 12.957143,
 'fiftyTwoWeekHigh': 23.5,
 'fiftyTwoWeekLow': 6.26,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 23122941,
 'forwardEps': -2.89,
 'forwardPE': -4.16955,
 'fromCurrency': None,
 'fullTimeEmployees': 185,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.15168001,
 'heldPercentInstitutions': 0.85837996,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/voyagertherapeutics.com',
 'longBusinessSummary': 'Voyager Therapeutics, Inc., a clinical-stage gene '
                        'therapy company, focuses on the development of '
                        'treatments for patients suffering from severe '
                        "neurological diseases. The company's lead clinical "
                        'candidate is the VY-AADC, which is in open-label '
                        'Phase 1b clinical trial for the treatment of '
                        "Parkinson's disease. Its preclinical programs "
                        'comprise VY-SOD102 for the treatment of amyotrophic '
                        "lateral sclerosis; VY-HTT01 for Huntington's disease; "
                        "VY-FXN01 for Friedreich's ataxia; Tau program for the "
                        "treatment of tauopathies, including Alzheimer's "
                        'disease, progressive supranuclear palsy, and '
                        'frontotemporal dementia; and alpha-synuclein program '
                        "for synucleinopathies, Parkinson's disease, Lewy Body "
                        'Dementia, and multiple system atrophy. The company '
                        'has strategic collaboration agreements with AbbVie '
                        'Inc.; the University of Massachusetts; and ClearPoint '
                        'Neuro, Inc., as well as collaborations with Brammer '
                        'Bio and Fujifilm Diosynth Biotechnologies to support '
                        'the development of its gene therapy programs. It also '
                        'has a collaboration and license agreement with '
                        'Neurocrine Biosciences, Inc. for the research, '
                        'development, and commercialization of '
                        'adeno-associated virus-based gene therapy products. '
                        'Voyager Therapeutics, Inc. was founded in 2013 and is '
                        'headquartered in Cambridge, Massachusetts.',
 'longName': 'Voyager Therapeutics, Inc.',
 'market': 'us_market',
 'marketCap': 448147936,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_256887902',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -40690000,
 'nextFiscalYearEnd': 1640908800,
 'open': 12.47,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '857 259 5340',
 'previousClose': 12.52,
 'priceHint': 2,
 'priceToBook': 5.5864625,
 'priceToSalesTrailing12Months': 3.8217988,
 'profitMargins': -0.347,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 12.7,
 'regularMarketDayLow': 12,
 'regularMarketOpen': 12.47,
 'regularMarketPreviousClose': 12.52,
 'regularMarketPrice': 12.47,
 'regularMarketVolume': 157168,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 37164600,
 'sharesPercentSharesOut': 0.084300004,
 'sharesShort': 3135625,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 3215104,
 'shortName': 'Voyager Therapeutics, Inc.',
 'shortPercentOfFloat': 0.1225,
 'shortRatio': 9.16,
 'startDate': None,
 'state': 'MA',
 'strikePrice': None,
 'symbol': 'VYGR',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -1.106,
 'twoHundredDayAverage': 11.683237,
 'volume': 157168,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.voyagertherapeutics.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '02139'}